Cargando…
“Ventilator-free days” composite outcome in patients with SARS-CoV-2 infection treated with tocilizumab: A retrospective competing risk analysis
BACKGROUND: SARS-CoV-2 infection demonstrates a wide range of severity, with more severe cases presenting with a cytokine storm with elevated serum interleukin-6; hence, the interleukin-6 receptor antibody tocilizumab was used for the management of severe cases. OBJECTIVE: To explore the effect of t...
Autores principales: | Mady, Ahmed F., Abdulrahman, Basheer, Mumtaz, Shahzad A., Al-Odat, Mohammed A., Kuhail, Ahmed, Altoraifi, Rehab, Alshae, Rayan, Alharthy, Abdulrahman M., Aletreby, Waleed Th. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242887/ https://www.ncbi.nlm.nih.gov/pubmed/35839546 http://dx.doi.org/10.1016/j.hrtlng.2022.06.024 |
Ejemplares similares
-
Effect of Tocilizumab on “Ventilator Free Days” Composite Outcome in SARS-CoV-2 Patients: A Retrospective Competing Risk Analysis
por: Mady, Ahmed F., et al.
Publicado: (2023) -
Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case series
por: Mady, Ahmed, et al.
Publicado: (2020) -
From Eye Drops to ICU, a Case Report of Three Side Effects of Ophthalmic Timolol Maleate in the Same Patient
por: Rana, Muhammad Asim, et al.
Publicado: (2015) -
Comparison of severity of immunized versus non-immunized COVID-19 patients admitted to ICU: A prospective observational study
por: Mhawish, Huda, et al.
Publicado: (2021) -
Deferoxamine in the management of COVID-19 adult patients admitted to ICU: a prospective observational cohort study
por: Almutary, Abdulaziz M., et al.
Publicado: (2023)